Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
BEIGENE NZ UNLIMITED,Zanubrutinib,Relapsed or refractory mantle cell lymphoma (R/R MCL),Zanubrutinib (BRUKINSA (for R/R MCL)),Options for investment,Community and Hospital,Oncology Agents and Immunosuppressants
